Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

Journal of Clinical Investigation

Volumn 118, Issue 9, 2008, Pages 3065-3074

  Carracedo, Arkaitz ^a,b   Ma, Li ^b,c,h   Teruya Feldstein, Julie ^b   Rojo, Federico ^d   Salmena, Leonardo ^a,b   Alimonti, Andrea ^a,b   Egia, Ainara ^a,b   Sasaki, Atsuo T ^a,e   Thomas, George ^f   Kozma, Sara C ^f   Papa, Antonella ^a,b   Nardella, Caterina ^a,b   Cantley, Lewis C ^a,e   Baselga, Jose ^d   Pandolfi, Pier Paolo ^a,b,g  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Weill Cornell Graduate School of Biomedical Sciences   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

^g NRB 1038 ^*  (United States)

^h WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN C1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; RAS PROTEIN; UNCLASSIFIED DRUG; WORTMANNIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; BREAST TUMOR; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; COLON TUMOR; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FEEDBACK SYSTEM; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LOW DRUG DOSE; MELANOMA; MONOTHERAPY; MOUSE; NEOPLASM; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROSTATE CANCER; SIGNAL TRANSDUCTION; SOLID TUMOR; TISSUE SECTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ENZYME ACTIVATION; ENZYME INHIBITORS; FEEDBACK, BIOCHEMICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASMS; SIROLIMUS; TRANSCRIPTION FACTORS;

EID: 51349164790     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34739     Document Type: Article

References (45)

1. Wullschleger, S., Loewith, R., and Hall, M.N. 2006. TOR signaling in growth and metabolism. Cell. 124:471-484.
2. Guertin, D.A., and Sabatini, D.M. 2007. Defining the role of mTOR in cancer. Cancer Cell. 12:9-22.
3. Ballif, B.A., et al. 2005. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl. Acad. Sci. U. S. A. 102:667-672.
4. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K.L. 2002. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4:648-657.
5. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P., and Pandolfi, P.P. 2005. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 121:179-193.
6. Manning, B.D., Tee, A.R., Logsdon, M.N., Blenis, J., and Cantley, L.C. 2002. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell. 10:151-162.
7. Inoki, K., Corradetti, M.N., and Guan, K.L. 2005. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 37:19-24.
8. Tee, A.R., and Blenis, J. 2005. mTOR, translational control and human disease. Semin. Cell Dev. Biol. 16:29-37.
9. Pearce, L.R., et al. 2007. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 405:513-522.
10. Sarbassov, D.D., Guertin, D.A., Ali, S.M., and Sabatini, D.M. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 307:1098-1101.
11. Faivre, S., Kroemer, G., and Raymond, E. 2006. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5:671-688.
12. Franz, D.N., et al. 2006. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann. Neurol. 59:490-498.
13. Cloughesy, T.F., et al. 2008. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5:e8.
14. Zhang, H., et al. 2007. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J. Clin. Invest. 117:730-738.
15. Zhang, H., et al. 2003. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112:1223-1233.
16. Harrington, L.S., et al. 2004. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 166:213-223.
17. Shah, O.J., Wang, Z., and Hunter, T. 2004. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 14:1650-1656.
18. O'Reilly, K.E., et al. 2006. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66:1500-1508.
19. Tabernero, J., et al. 2008. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J. Clin. Oncol. 26:1603-1610.
20. Brown, A.P., Carlson, T.C., Loi, C.M., and Graziano, M.J. 2007. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother. Pharmacol. 59:671-679.
21. Kohno, M., and Pouyssegur, J. 2006. Targeting the ERK signaling pathway in cancer therapy. Ann. Med. 38:200-211.
22. Wang, J.Y., Wilcoxen, K.M., Nomoto, K., and Wu, S. 2007. Recent advances of MEK inhibitors and their clinical progress. Curr. Top. Med. Chem. 7:1364-1378.
23. Ma, L., et al. 2005. Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes Dev. 19:1779-1786.
24. Manning, B.D., et al. 2005. Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 19:1773-1778.
25. Im, E., et al. 2002. Rheb is in a high activation state and inhibits B-Raf kinase in mammalian cells. Oncogene. 21:6356-6365.
26. Karbowniczek, M., et al. 2004. Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem. 279:29930-29937.
27. Karbowniczek, M., Robertson, G.P., and Henske, E.P. 2006. Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization. J. Biol. Chem. 281:25447-25456.
28. Gupta, S., et al. 2007. Binding of ras to phosphoinositide 3-kinase p110alpha is required for rasdriven tumorigenesis in mice. Cell. 129:957-968.
29. Rodriguez-Viciana, P., et al. 1994. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 370:527-532.
30. Ma, L., et al. 2007. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 67:7106-7112.
31. Wennstrom, S., and Downward, J. 1999. Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor. Mol. Cell. Biol. 19:4279-4288.
32. Sampaio, C., et al. 2008. Signal strength dictates PI3K contribution to Ras/ERK1-2 activation via differential Gab1/Shp2 recruitment: consequences for resistance to EGFR inhibition. Mol. Cell. Biol. 28:587-600.
33. Wells, V., Downward, J., and Mallucci, L. 2007. Functional inhibition of PI3K by the betaGBP molecule suppresses Ras-MAPK signalling to block cell proliferation. Oncogene. 26:7709-7714.
34. Breslin, E.M., White, P.C., Shore, A.M., Clement, M., and Brennan, P. 2005. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br. J. Pharmacol. 144:791-800.
35. Ikezoe, T., et al. 2007. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk. Res. 31:673-682.
36. Tamburini, J., et al. 2008. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood. 111:379-382.
37. Fan, Q.W., et al. 2007. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 67:7960-7965.
38. Hennessy, B.T., Smith, D.L., Ram, P.T., Lu, Y., and Mills, G.B. 2005. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4:988-1004.
39. Buck, E., et al. 2006. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther. 5:2676-2684.
40. Wang, L.H., Chan, J.L., and Li, W. 2007. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int. J. Cancer. 121:157-164.
41. Wang, M.Y., et al. 2006. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 66:7864-7869.
42. Oliveira, J.C., et al. 2008. Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts. J. Cancer Res. Clin. Oncol. 134:833-839.
43. Kinkade, C.W., et al. 2008. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 118:3051-3064.
44. Maeda, T., et al. 2005. Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature. 433:278-285.
45. Chen, Z., et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 436:725-730.